References
- Amundadottir LT, Leder P (1998). Signal transduction pathways activated and required for mammary carcinogenesis in response to specific oncogenes. Oncogene, 16, 737-46. https://doi.org/10.1038/sj.onc.1201829
- Carmeliet P (2003). Angiogenesis in health and disease. Nat Med, 9, 653-60. https://doi.org/10.1038/nm0603-653
- Carmeliet P, Base M (2008). Metabolism and therapeutic angiogenesis. N Engl J Med, 358, 2511-2. https://doi.org/10.1056/NEJMcibr0802500
- Carmeliet P, Jain RK (2000). Angiogenesis in cancer and other diseases. Nature, 407, 249-57. https://doi.org/10.1038/35025220
- Davidson B, Konstantinovsky S, Kleinberg L, et al (2006). The mitogen-activated protein kinases (MAPK). p38 and JNK are markers of tumor progression in breast carcinoma. Gynecol Oncol, 102, 453-61. https://doi.org/10.1016/j.ygyno.2006.01.034
- Fan TP, Yeh JC, Leung KW, Yue PY, Wong RN (2006). Angiogenesis: from plants to blood vessels. Trends Pharmacol Sci, 27, 297-309. https://doi.org/10.1016/j.tips.2006.04.006
- Ferrara N, Kerbel RS (2005). Angiogenesis as a therapeutic target. Nature, 438, 967-74. https://doi.org/10.1038/nature04483
- Folkman J (1971). Tumor angiogenesis: therapeutic implications. N Engl J Med, 285, 1182-6. https://doi.org/10.1056/NEJM197111182852108
- Folkman J, Shing Y (1992). Angiogenesis. J Biol Chem, 267, 10931-4.
- Gupta GP, Massague J (2006). Cancer metastasis: building a framework. Cell, 127, 679-95. https://doi.org/10.1016/j.cell.2006.11.001
- Johnson GL, Lapadat R (2002). Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science, 298, 1911-2. https://doi.org/10.1126/science.1072682
- Hsia DA, Mitra SK, Hauck CR, et al (2003). Differential regulation of cell motility and invasion by FAK. J Cell Biol, 160, 753-67. https://doi.org/10.1083/jcb.200212114
- Huang D, Ding Y, Luo WM, et al (2008). Inhibition of MAPK Kinase signaling pathways suppressed renal cell carcinoma growth and angiogenesis in vivo. Cancer Res, 68, 81-8. https://doi.org/10.1158/0008-5472.CAN-07-5311
- Kruger EA, Duray PH, Price DK, Pluda JM, Figg WD (2001). Approaches to preclinical screening of antiangiogenic agents. Semin Oncol, 28, 570-6. https://doi.org/10.1016/S0093-7754(01)90026-0
- Lee JC, Laydon JT, Mcdonnell PC, et al (1994). A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature, 372, 739-46. https://doi.org/10.1038/372739a0
- Li X, Wang X, Ye H, Peng A, Chen L (2012). Barbigerone, an isoflavone, inhibits tumor angiogenesis and human non-smallcell lung cancer xenografts growth through VEGFR2 signaling pathways.Cancer Chemother Pharmacol, 70, 425-37. https://doi.org/10.1007/s00280-012-1923-x
- Olson MF, Sahai E (2009). The actin cytoskeleton in cancer cell motility. Clin Exp Metastasis, 26, 273-87. https://doi.org/10.1007/s10585-008-9174-2
- Patan S (2004). Vasculogenesis and angiogenesis. Cancer Treat Res, 117, 3-32. https://doi.org/10.1007/978-1-4419-8871-3_1
- Raingeaud J, Gupta S, Rogers JS, et al (1995). Pro-inflammatory cytokines and environmental stress cause p38 mitogenactivated protein kinase activation by dual phosphorylation on tyrosine and threonine. J. Biol. Chem, 31, 270, 7420-6. https://doi.org/10.1074/jbc.270.13.7420
- Reddy KB, Nabha SM, Atanaskova N (2003). Role of MAP kinase in tumor progression and invasion. Cancer Metastasis Rev, 22, 395-403. https://doi.org/10.1023/A:1023781114568
- Small JV, Rottner K, Kaverina I, Anderson KI (1998). Assembling an actin cytoskeleton for cell attachment and movement. Biochim Biophys Acta, 1404, 271-81. https://doi.org/10.1016/S0167-4889(98)00080-9
- Tournaire R, Simon MP, le Noble F, et al (2004). A short synthetic peptide inhibits signal transduction, migration and angiogenesis mediated by Tie2 receptor. EMBO Rep, 5, 262-7. https://doi.org/10.1038/sj.embor.7400100
- Tozer GM, Kanthou C, Baguley BC (2005). Disrupting tumor blood vessels. Nat Rev Cancer, 5, 423-35. https://doi.org/10.1038/nrc1628
- Uzgare AR, Kaplan PJ, Greenberg NM (2003). Differential expression and/or activation of P38MAPK, erk1/2, and jnk during the initiation and progression of prostate cancer. Prostate, 55, 128-39. https://doi.org/10.1002/pros.10212
- Vicent S, Garayoa M, Lopez-Picazo JM, et al (2004). Mitogenactivated protein kinase phosphatase-1 is overexpressed in non-small cell lung cancer and is an independent predictor of outcome in patients. Clin Cancer Res, 10, 3639-49. https://doi.org/10.1158/1078-0432.CCR-03-0771
- Vilain C (1980). Barbigerone, a new pyranoisoflavone from seeds of Tephrosia barbigera. Phytochem, 19, 988-9. https://doi.org/10.1016/0031-9422(80)85162-4
- Wangensteen H, Alamgir M, Rajia S, Samuelsen AB, Malterud KE (2005). Rotenoids and isoflavones from Sarcolobus globosus. Planta Med, 71, 754-8. https://doi.org/10.1055/s-2005-864182
- Wangensteen H, Miron A, Alamgir M, et al (2006). Antioxidant and 15-lipoxygenase inhibitory activity of rotenoids, isoflavones and phenolic glycosides from Sarcolobus globosus. Fitoterapia, 77, 290-5. https://doi.org/10.1016/j.fitote.2006.03.017
- Webb CP, Van Aelst L, Wigler MH, Woude GF (1998). Signaling pathways in Ras-mediated tumorigenicity and metastasis. Proc Natl Acad Sci USA, 95, 8773-8. https://doi.org/10.1073/pnas.95.15.8773
- Ye HY, Zhong SJ, Li YF, et al (2010). Enrichment and isolation of barbigerone from Millettia pachycarpa Benth. using highspeed counter-current chromatography and preparative HPLC. J Sep Sci, 33, 1010-7.
- Yenesew A, Derese S, Midiwo JO, Oketch-Rabah HA, Lisgarten J, Palmer R, et al (2003). Anti-plasmodial activities and X-ray crystal structures of rotenoids from Millettia usaramensis subspecies usaramensis". Phytochem, 64, 773-9. https://doi.org/10.1016/S0031-9422(03)00373-X
- Yenesew A, Midiwo JO, Waterman PG (1998). Rotenoids, isoflavones and chalcones from the stem bark of Millettia usaramensis subspecies usaramensis. Phytochem, 47, 295-300. https://doi.org/10.1016/S0031-9422(97)00424-X
- Zhao CJ, Yang HS, Shi HS, et al (2011). Distinct Contributions of Angiogenesis and Vascular Co-option during the Initiation of Microtumors and Micrometastases. Carcinogenesis, 32, 1143-50. https://doi.org/10.1093/carcin/bgr076
- Zhang D, Li B, Shi J, et al (2010). Suppression of Tumor Growth and Metastasis by Simultaneously Blocking Vascular Endothelial Growth Factor (VEGF).-A and VEGF-C with a Receptor-Immunoglobulin Fusion Protein. Cancer Res, 70, 2495-503. https://doi.org/10.1158/0008-5472.CAN-09-3488
Cited by
- Biological Screening of Novel Derivatives of Valproic Acid for Anticancer and Antiangiogenic Properties vol.15, pp.18, 2014, https://doi.org/10.7314/APJCP.2014.15.18.7785
- Different Immunology Mechanisms of Phellinus igniarius in Inhibiting Growth of Liver Cancer and Melanoma Cells vol.15, pp.8, 2014, https://doi.org/10.7314/APJCP.2014.15.8.3659
- The promise of zebrafish as a chemical screening tool in cancer therapy vol.7, pp.11, 2015, https://doi.org/10.4155/fmc.15.73
- Barbigerone-in-hydroxypropyl-β-cyclodextrin-liposomal nanoparticle: preparation, characterization and anti-cancer activities vol.82, pp.3-4, 2015, https://doi.org/10.1007/s10847-015-0533-8
- Utilizing Zebrafish to Identify Anti-(Lymph)Angiogenic Compounds for Cancer Treatment: Promise and Future Challenges vol.23, pp.6, 2016, https://doi.org/10.1111/micc.12289
- Patient-derived xenograft in zebrafish embryos: a new platform for translational research in neuroendocrine tumors vol.57, pp.2, 2017, https://doi.org/10.1007/s12020-016-1048-9
- A novel synthetic small molecule YF-452 inhibits tumor growth through antiangiogenesis by suppressing VEGF receptor 2 signaling vol.60, pp.2, 2017, https://doi.org/10.1007/s11427-016-0369-6
- New insights into the antiangiogenic and proangiogenic properties of dietary polyphenols vol.61, pp.6, 2017, https://doi.org/10.1002/mnfr.201600912
- Macrophages enhance Vegfa-driven angiogenesis in an embryonic zebrafish tumour xenograft model vol.11, pp.12, 2018, https://doi.org/10.1242/dmm.035998